GH Stock Price Today (July 2026) — Guardant Health, Inc. Analysis & Key Metrics 2026-07-17
Guardant Health, Inc. (GH) is trading at $155.87, up 0.56% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $144.42 (-7.3% upside).
- Volatility remains elevated (60.55% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (48.30% YoY) alongside significant competitive pressures.
GH Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Guardant Health, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $20.50B
P/E Ratio
Forward P/E: -430.62
Revenue Growth
Year over Year
Analyst Target
+-7.3% upside potential
Key Investor Questions About GH
What investors need to know before buying
Based on current market data, GH presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 52.36)
- Fundamentals say: Mixed signals (nuanced financial profile)
GH's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for GH investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $1.70B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, GH stock traded between $40.35 and $168.74—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 60.55% annualized volatility and β=1.15, the stock exhibits moderate correlation to market moves—making GH suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Alamar Hits A High Note On Alzheimer's Buzz
If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.
Freenome colorectal cancer test data improve on earlier results
The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.
Will Expanded Coverage of Guardant’s Shield Test Reshape UnitedHealth Group’s (UNH) Preventive Care Narrative?
In July 2026, Guardant Health announced that its Shield blood test for colorectal cancer screening is now covered for eligible UnitedHealth Group members aged 45 and over, extending access to this noninvasive option across roughly 40 million people in employer, individual and Medicare-related plans amid rising colorectal cancer rates in younger adults. This move highlights UnitedHealth Group’s role in broadening access to newer cancer screening technologies, potentially reshaping how its...
Cancer Blood Screen SPAC Merger Is Delayed by Test’s Results
Thursday was the day set for shareholders to approve the merger of special-purpose acquisition company Perceptive Capital Solutions with cancer screening firm Freenome. The resulting public company will compete with Guardant Health Grail and Natera in a market for cancer-detecting blood tests that they hope will eventually be worth more than $30 billion a year. The study shows Freenome’s updated SimpleScreen CRC test was somewhat less sensitive to cancers, overall, than Guardant’s Shield test, but the Freenome test was more sensitive to precancerous growths.
The Surprising Reason Guardant Health, A Top 3% Stock, Soared To A Five-Year High
Guardant Health stock jumped Thursday after key competitor, Freenome, unveiled study results for its colon cancer blood test.
UnitedHealth Group (UNH) Opens Shield Blood Test Coverage For Adults 45 And Older
UnitedHealth Group (NYSE:UNH) has become the first major commercial insurer to cover Guardant Health's Shield blood test for early colorectal cancer screening. The new coverage applies to eligible adults aged 45 and older, expanding access to a blood-based alternative to traditional screening methods. For investors watching UnitedHealth Group, this coverage decision highlights how the insurer is using its scale to shape access to emerging screening tools. The stock last closed at $417.99,...
Planet Labs Upgraded, Royal Caribbean Downgraded: Updated Rankings on Top Blue-Chip Stocks
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise my Stock Grader recommendations for 116 big blue chips. Chances are that you have at least one of these stocks in your portfolio, so you may want to give this list a skim and act accordingly. This Week’s Ratings Changes: Up
Guardant Health stock surges on colon cancer blood test news
Guardant Health (GH) investors have a new number to think about this week. Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175. Bernstein also kept its Outperform rating intact. The new price target came less than a day after a ...
Guardant Health (GH) Stock May Look Fully Valued Following Shield Coverage News
Guardant Health stock has surged very sharply over the past three years, yet its valuation checks suggest the current share price is no longer a clear bargain, with the Discounted Cash Flow (DCF) estimate pointing to roughly fair value while market based multiples signal an expensive profile. The share price has delivered about 351.7% over three years, which puts more pressure on current buyers to justify the move with future cash flows. Expanded insurance coverage for the Shield blood test...
Why Guardant Health (GH) Is Up 12.6% After Joining the Russell 1000 and Major Indexes – And What's Next
On 27 June 2026, Guardant Health, Inc. was added to a wide range of major Russell indices, including the Russell 1000, Russell Midcap, multiple growth and value benchmarks, and was concurrently removed from several Russell 2000 segments. This broad index migration effectively reclassifies Guardant Health as a larger-cap name in benchmark terms, potentially increasing its visibility among institutional investors and index-tracking funds. Next, we’ll examine how Guardant Health’s shift into...
Frequently Asked Questions
Common investor questions about Guardant Health, Inc.
Guardant Health, Inc. (GH) is currently trading at $155.87. The RSI (14-day) is at 52.4, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $144.42 implies 7.3% downside from current levels. Volatility is high at 60.6% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Guardant Health, Inc. (GH): The trailing P/E ratio is -45.71, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -430.62, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is -122.54. Price-to-Sales is 19.13. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering GH, the consensus price target is $144.42. This represents a 7.3% downside from the current price of $155.87. The range spans from a low target of $90.00 to a high target of $190.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Guardant Health, Inc. (GH) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Guardant Health, Inc. (GH) investors include: 1. High volatility (60.6% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (10.3% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Guardant Health, Inc.'s (GH) current debt and financial health profile: Total debt stands at $1.70B. The current ratio is 4.68, indicating strong short-term liquidity. The quick ratio is 4.25. The company holds $1.10B in cash and equivalents. Free cash flow is negative at $-85,448,128, which could limit the company's ability to manage debt obligations.